by Ludwig Burger
Frankfurt (Reuters) – Novartis published more optimistic annual prospects on Tuesday, the group citing the solid growth of its drugs such as Leqvio, Kisqali and Kesmpta in the first quarter.
The Swiss pharmaceutical group said in a statement anticipate an increase in the “two -digit low range” of its operating profit outside exceptional elements.
Previously, he tapped on an increase between the “high fork with a figure and the two -digit low range” after a leap of 22% in 2024.
Over the first three months of the year, the group recorded a 22% increase in its net profit outside exceptional items, which established $ 4.48 billion (3.94 billion euros) while analysts were tabling on approximately $ 4.2 billion.
Among the products that have exceeded expectations, the Kisqali breast cancer medication saw its sales increase by $ 52% to $ 956 million, while those of the hypocholesterolemic Leqvio medication jumped from $ 70% to 257 million dollars after threesome.
Earlier months, Novartis said its intention to invest $ 23 billion in order to enlarge 10 sites in the United States in response to new threats from the Trump administration as to the importation of pharmaceutical products.
(Written by Ludwig Burger, Pauline Foret, edited by Augustin Turpin)
Copyright © 2025 Thomson Reuters
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
